ENZ, TF, THM, RFA - Stock News From DrStockPick.com!

Dec. 14, 2010 - PRLog -- Enzo Biochem, Inc.  reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

Among the quarter’s highlights (all references are to sequential quarter over quarter results, normalized for an inventory charge and severance of $1.8 million where applicable):

   * Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
   * Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
   * Company-wide, gross margin increased $2.0 million or 17%.
   * Operating expenses decreased 7%, or to 57% of revenues, from 63%.
   * EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
   * Net loss for the quarter was reduced 70%.

Enzo Biochem is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

Founded in 1976, Enzo Biochem has concentrated on the development of enabling technologies in the areas of gene regulation and gene modification. Many of Enzo Biochem's technologies are applicable to the biomedical and pharmaceutical research markets, and are further using these technologies as a platform for our entry into the clinical diagnostics market. Today, Enzo technologies and products are recognized as the key tools in non-radioactive gene labeling used by researchers worldwide.

Additionally, Enzo's work in gene analysis has led to development of a number of significant therapeutic candidates for the treatment of viral and immunological based disorders, several of which are in various phases of human clinical trials. In the course of Enzo Biochem's extensive research and development activities, they have built a significant patent position consisting of numerous pioneer patents and applications that encompass core technologies.

*************************************************

Thai Capital Fund Inc.  announced an ordinary income dividend of U.S. $0.06 per share, a net short term capital gain distribution of U.S. $1.59 per share and a net long term capital gain distribution of U.S. $1.46 per share. Shareholders who participate in the Fund’s Dividend Reinvestment Plan will receive an equivalent dividend amount in shares of the Fund. The dividend will be payable on December 30, 2010 to the shareholders of record at the close of business on December 20, 2010. The ex-dividend date will be December 16, 2010.

Thai Capital Fund Inc. is a closed-ended equity mutual fund launched by Siam Commercial Bank Asset Management Co. Ltd. It is managed by Daiwa SB Investments (Hong Kong).

*************************************************

International Tower Hill Mines Ltd.  is pleased to provide an operational update at its Livengood Gold Project near Fairbanks, Alaska. The Company has achieved key milestones in advancing the Livengood project’s pre-feasibility study (PFS) and adding key members to its development team.

International Tower Hill Mines Ltd. engages in acquiring, exploring, and evaluating mineral properties in Alaska and Nevada.

*************************************************

BlackRock Investment Quality Municipal Income Trust  announced distributions and special distributions. Several of the Funds announced dividend increases. These dividend increases take into account each Fund’s earnings potential in light of the current market environment. In addition, several other Funds announced dividend reductions. Generally, these dividend reductions were made in order to better align the Funds with their current earnings rates in light of the current market environment.

BlackRock is a leader in investment management, risk management and advisory services for institutional and retail clients worldwide. At September 30, 2010, BlackRock’s AUM was $3.446 trillion.


***************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.